Polish healthtech startup Infermedica raises USD 30 million in Series B

Poland-based Infermedica, an AI-driven healthtech platform providing users with pre-diagnosis and triage services powered by AI, raised USD 30 million on 26th January 2022.

Investors: The investment round was led by One Peak and supported by existing investors Karma Ventures, European Bank for Reconstruction and Development, Heal Capital, and Inovo Venture Partners. The startup has raised USD 45 million, including previous funding rounds.

Purpose of funding: The startup plans further to develop its MGP (Medical Guidance Platform) and add new modules to cover the startup’s entire primary care journey. The focus will be on improving customer experience and back-end functionality. Additionally, the startup will expand its international team of professionals and boost its global commercial presence.

About Infermedica

Founded in 2012 by Irving Loh, Piotr Orzechowski, and Roberto Sicconi, Infermedica is located in Wroclaw, Poland. Infermedica is an AI-driven healthtech platform providing users with pre-diagnosis and triage services powered by AI. The startup aims to ease the strain on global healthcare systems and make healthcare more convenient, affordable, and accessible by automating primary care. The startup’s platform MGP (Medical Guidance Platform) streamlines healthcare decision-making and supports the symptom-to-outcome process.

Moreover, the company relies on artificial intelligence and machine learning to identify patterns in data. Nevertheless, the team of physicians verifies each element of the medical database to ensure that patients trust recommendations. In recent years, growth has been robust. The startup has performed eight million health checkups across thirty countries in nineteen languages with a 93 percent diagnostic engine accuracy. Microsoft, Allianz Partners, Everyday Health, getwell network, Sana Kliniken, and others are among the startup’s clients. 

What the founder has to say

“To date, we’ve spent over 60,000 hours of physicians’ work building one of the world’s most advanced medical knowledge bases of diseases, symptoms, and risk factors. We will deploy the new funds to execute our vision of making primary care more efficient and affordable by creating constantly improving AI technology for everyone on the planet,” said Piotr Orzechowski, CEO and Co-Founder at Infermedica.

What the client has to say

“At Sana, our Symptom Checker, which is based on Infermedica’s technology, is directed towards patients and helps patients to understand and assess their symptoms. But the application also helps us better understand what kind of treatment our patients require. These insights are evaluated and translated into actions which allow us to improve further the way we care for our patients,” said Michael Rosenstock, Head of Sana Digital, at Sana Kliniken.

---

 For more extensive analysis and Market Intelligence reports feel free to approach us or visit our website: Venture Capital Market Intelligence Reports | VCBay.

We try our 2022 best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know

-if there are any discrepancies in any of our published stories,

-how we can improve,

-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback and thank you for stopping by!

Next Article